New drug targets tough cancers with KRas G12V mutation
NCT ID NCT07650357
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke Cancer Institute
Durham, North Carolina, 27701, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
Contact Phone: •••-•••-••••
-
Sarah Cannon Research Institute (SCRI) Oncology Partners
Nashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLSP-5282 (an experimental drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with certain hard-to-treat cancers that have a specific genetic mutation.
What could go wrong
This is a very early (Phase 1) trial with only 140 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.